Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals.

Hemo B, Endevelt R, Porath A, Stampfer MJ, Shai I.

Diabetes Res Clin Pract. 2011 Nov;94(2):269-75. doi: 10.1016/j.diabres.2011.08.021. Epub 2011 Sep 9.

PMID:
21907442
2.

[Pharmacological therapy of obesity].

Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian.

PMID:
18773755
3.

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.

Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, Guvener N.

Diabetes Obes Metab. 2002 Jan;4(1):49-55.

PMID:
11874442
4.

Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.

Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.

Diabetes Nutr Metab. 2004 Aug;17(4):222-9.

PMID:
15575343
5.

Comparison of orlistat and sibutramine in an obesity management program: efficacy, compliance, and weight regain after noncompliance.

Gursoy A, Erdogan MF, Cin MO, Cesur M, Baskal N.

Eat Weight Disord. 2006 Dec;11(4):e127-32.

PMID:
17272944
6.
7.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2004;(3):CD004094. Review.

PMID:
15266516
8.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2003;(4):CD004094. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD004094.

PMID:
14584004
9.

Comparison of efficacy of sibutramine or orlistat versus their combination in obese women.

Sari R, Balci MK, Cakir M, Altunbas H, Karayalcin U.

Endocr Res. 2004 May;30(2):159-67.

PMID:
15473126
10.

Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.

Johansson K, Sundström J, Neovius K, Rössner S, Neovius M.

Obes Rev. 2010 Nov;11(11):777-91. doi: 10.1111/j.1467-789X.2009.00693.x. Review.

PMID:
20025693
11.

Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.

Czernichow S, Knol MJ, Fezeu L, Grobbee DE.

Eur J Prev Cardiol. 2012 Jun;19(3):484-9. doi: 10.1177/1741826711406058. Epub 2011 Apr 4.

PMID:
21464100
12.

NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.

Erondu N, Addy C, Lu K, Mallick M, Musser B, Gantz I, Proietto J, Astrup A, Toubro S, Rissannen AM, Tonstad S, Haynes WG, Gottesdiener KM, Kaufman KD, Amatruda JM, Heymsfield SB.

Obesity (Silver Spring). 2007 Aug;15(8):2027-42.

13.

X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.

Diabetes Obes Metab. 2005 Nov;7(6):699-708.

PMID:
16219013
14.

The effectiveness of pharmaceutical interventions for obesity: weight loss with orlistat and sibutramine in a United Kingdom population-based cohort.

Douglas IJ, Bhaskaran K, Batterham RL, Smeeth L.

Br J Clin Pharmacol. 2015 Jun;79(6):1020-7. doi: 10.1111/bcp.12578.

15.

Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.

Elfhag K, Finer N, Rössner S.

Diabetes Obes Metab. 2008 Jun;10(6):498-505. Epub 2007 Jun 26.

PMID:
17593239
16.

Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?

Aydin N, Topsever P, Kaya A, Karasakal M, Duman C, Dağar A.

Tohoku J Exp Med. 2004 Mar;202(3):173-80.

17.

Weight management and current options in pharmacotherapy: orlistat and sibutramine.

Leung WY, Thomas GN, Chan JC, Tomlinson B.

Clin Ther. 2003 Jan;25(1):58-80. Review.

PMID:
12637112
18.

Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.

Sánchez-Reyes L, Fanghänel G, Yamamoto J, Martínez-Rivas L, Campos-Franco E, Berber A.

Clin Ther. 2004 Sep;26(9):1427-35.

PMID:
15531005
19.

Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.

Chou KM, Huang BY, Fanchiang JK, Chen CH.

Chang Gung Med J. 2007 Nov-Dec;30(6):538-46.

20.

Orlistat and sibutramine beyond weight loss.

Mannucci E, Dicembrini I, Rotella F, Rotella CM.

Nutr Metab Cardiovasc Dis. 2008 Jun;18(5):342-8. Epub 2007 Oct 24.

PMID:
17928208
Items per page

Supplemental Content

Write to the Help Desk